Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
University of Iowa, Iowa City, Iowa Markey Cancer Center, Lexington, Kentucky St. Luke's University Health Network, Easton, Pennsylvania Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Last updated February 2026